

## **RCINJ Gastrointestinal / Colorectal Tumor Board**

**This activity is provided by Rutgers Cancer Institute of New Jersey, Rutgers Robert Wood Johnson Medical School,  
Department of Radiology and Department of Pathology.**

**Interesting Cases Week of August 20, 2019  
Rutgers Cancer Institute of New Jersey  
195 Little Albany Street 1st Floor Aud. A  
New Brunswick NJ 08903  
August 20, 2019 8:00am – 9:00am**

### **Case Presenter Salma Jabbour, MD**

At the conclusion of this activity, participants will be better able to:

- Identify alternative courses of treatment with presenting options to improve specific patient outcomes and quality of life.
- Correlate and integrate the clinical oncologic diagnosis with the pathologic, radiologic, and surgical findings of the cases presented.
- Analyze oncological provider's opinions to identify approaches to patient management and care.
- Discuss clinical trials specific eligibility criteria and treatment protocols.

**Target Audience:** This activity is designed for medical oncologists, surgical oncologists, general surgeons, radiation oncologists, radiologists, gastroenterologists, pathologists, physician assistants, nurses and nurse practitioners.

#### **Accreditation & Designation Statements**



In support of improving patient care, Rutgers Biomedical and Health Sciences is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

**Physicians:** Rutgers Biomedical and Health Sciences designates this live activity for a maximum of 1 *AMA PRA Category 1 Credit*<sup>™</sup>. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

**Nurses:** This activity is awarded 1 contact hours. (60-minute CH)

#### **Disclosure Declarations:**

Dr. Jabbour have no relevant financial relationships to disclose.

Speakers are required to disclose discussion of off-label/investigational uses of commercial products/devices in their presentation. These disclosures will be made to the audience at the time of the activity.

Planning Committee: Dr. Carpizo has disclosed the following relevant financial relationships: Scientific Founder - Z53 Therapeutics. Drs. Jabbour and Mrs. Librizzi have no relevant financial relationships to disclose.